Response to Kang et al, 'Efficacy of Low-Dose Oral Minoxidil in the Management of Anticancer Therapy-Induced Alopecia in Patients with Breast Cancer: A Retrospective Cohort Study'

The document discusses the findings of Kang et al.'s study on the efficacy of low-dose oral minoxidil (LDOM) combined with topical minoxidil for managing chemotherapy-induced alopecia in breast cancer patients. The study found that the combination therapy improved hair density more than topical minoxidil alone. However, 13.5% of patients on combination therapy experienced hypertrichosis, compared to 0% on topical minoxidil alone. The authors suggest further research to compare LDOM monotherapy with combination therapy, as LDOM monotherapy may avoid issues like cost and skin irritation associated with topical minoxidil. The study highlights the need for more research on minoxidil's role in treating cancer-related alopecia.